Christopher J. Duff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christopher J. Duff has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Hugh Heald
University of Manchester Manchester UK
11 shared publications - Anthony A. Fryer
School of Medicine, Keele University, Keele, UK
11 shared publications - Mike Stedman
RES Consortium, Andover, UK
7 shared publications - Pensee Wu
School of Medicine, Keele University, Keele, UK
6 shared publications - Fahmy W. F. Hanna
Department of Diabetes and Endocrinology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK
5 shared publications - Lewis Green
Department of Clinical Biochemistry, St. Helens & Knowsley Teaching Hospitals NHS Trust, Whiston Hospital, Prescot, UK
5 shared publications
Latest Publications
- Open Access
- 1 December 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (2) , 565-566
Correction to: Is the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion
- 1 December 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (2) , 565-566
Open AccessCorrection to: Is the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion
- Open Access
- 30 September 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (1) , 99-110
Is the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion
Introduction Women are on average diagnosed with diabetes mellitus at later age than men but have higher mortality. As the diagnosis of diabetes mellitus is primarily based on HbA1c, the use of a non-specific reference range and cut point for diabetes mellitus that does not account for gender differences in diabetes could potentially lead to underdiagnosis of diabetes mellitus in women and missed opportunities for intervention. We investigated whether a contributing factor to the later diagnosis in women may be a difference in distribution of HbA1c in premenopausal women versus men of the same age by comparing HbA1c values in men and women across multiple sites in the UK. Methods We analysed the HbA1c levels of 146,907 individuals who underwent single testing only and had HbA1c ≤ 50 mmol/mol between 2012 and 2019 in one laboratory (cohort 1). This was replicated in six laboratories with 938,678 individuals tested between 2019 and 2021 (cohort 2). Results In cohort 1, women < 50 years old had an HbA1c distribution markedly lower than that in men by a mean of 1.6 mmol/mol (p < 0.0001), while the difference in the distribution of HbA1c for individuals aged ≥ 50 years was less pronounced (mean difference 0.9 mmol/mol, p < 0.0001). For individuals under the age of 50, HbA1c in women lagged by up to 10 years compared to men. Similar findings were found in cohort 2. We estimated an additional 17% (n = 34,953) of undiagnosed women aged < 50 years in England and Wales could be reclassified to have diabetes mellitus, which may contribute to up to 64% of the difference in mortality rates between men/women with diabetes mellitus aged 16–50 years. Conclusion The HbA1c cut point for diagnosis of diabetes mellitus may need to be re-evaluated in women under the age of 50 years. Early identification of diabetes mellitus in women has the potential to improve women’s health outcomes in the longer term.
- 30 September 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (1) , 99-110
Open AccessIs the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion
Introduction Women are on average diagnosed with diabetes mellitus at later age than men but have higher mortality. As the diagnosis of diabetes mellitus is primarily based on HbA1c, the use of a non-specific reference range and cut point for diabetes mellitus that does not account for gender differences in diabetes could potentially lead to underdiagnosis of diabetes mellitus in women and missed opportunities for intervention. We investigated whether a contributing factor to the later diagnosis in women may be a difference in distribution of HbA1c in premenopausal women versus men of the same age by comparing HbA1c values in men and women across multiple sites in the UK. Methods We analysed the HbA1c levels of 146,907 individuals who underwent single testing only and had HbA1c ≤ 50 mmol/mol between 2012 and 2019 in one laboratory (cohort 1). This was replicated in six laboratories with 938,678 individuals tested between 2019 and 2021 (cohort 2). Results In cohort 1, women < 50 years old had an HbA1c distribution markedly lower than that in men by a mean of 1.6 mmol/mol (p < 0.0001), while the difference in the distribution of HbA1c for individuals aged ≥ 50 years was less pronounced (mean difference 0.9 mmol/mol, p < 0.0001). For individuals under the age of 50, HbA1c in women lagged by up to 10 years compared to men. Similar findings were found in cohort 2. We estimated an additional 17% (n = 34,953) of undiagnosed women aged < 50 years in England and Wales could be reclassified to have diabetes mellitus, which may contribute to up to 64% of the difference in mortality rates between men/women with diabetes mellitus aged 16–50 years. Conclusion The HbA1c cut point for diagnosis of diabetes mellitus may need to be re-evaluated in women under the age of 50 years. Early identification of diabetes mellitus in women has the potential to improve women’s health outcomes in the longer term.
- Open Access
- 22 February 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 14 (4) , 691-707
The Effect of the COVID-19 Pandemic on HbA1c Testing: Prioritization of High-Risk Cases and Impact of Social Deprivation
Introduction Studies show that the COVID-19 pandemic disproportionately affected people with diabetes and those from disadvantaged backgrounds. During the first 6 months of the UK lockdown, > 6.6 M glycated haemoglobin (HbA1c) tests were missed. We now report variability in the recovery of HbA1c testing, and its association with diabetes control and demographic characteristics. Methods In a service evaluation, we examined HbA1c testing across ten UK sites (representing 9.9% of England’s population) from January 2019 to December 2021. We compared monthly requests from April 2020 to those in the equivalent 2019 months. We examined effects of (i) HbA1c level, (ii) between-practice variability, and (iii) practice demographics. Results In April 2020, monthly requests dropped to 7.9–18.1% of 2019 volumes. By July 2020, testing had recovered to 61.7–86.9% of 2019 levels. During April–June 2020, we observed a 5.1-fold variation in the reduction of HbA1c testing between general practices (12.4–63.8% of 2019 levels). There was evidence of limited prioritization of testing for patients with HbA1c > 86 mmol/mol during April–June 2020 (4.6% of total tests vs. 2.6% during 2019). Testing in areas with the highest social disadvantage was lower during the first lockdown (April–June 2020; trend test p < 0.001) and two subsequent periods (July–September and October–December 2020; both p < 0.001). By February 2021, testing in the highest deprivation group had a cumulative fall in testing of 34.9% of 2019 levels versus 24.6% in those in the lowest group. Conclusion Our findings highlight that the pandemic response had a major impact on diabetes monitoring and screening. Despite limited test prioritization in the > 86 mmol/mol group, this failed to acknowledge that those in the 59–86 mmol/mol group require consistent monitoring to achieve the best outcomes. Our findings provide additional evidence that those from poorer backgrounds were disproportionately disadvantaged. Healthcare services should redress this health inequality.
- 22 February 2023
- Published by Springer Nature in Diabetes Therapy
- Vol. 14 (4) , 691-707
Open AccessThe Effect of the COVID-19 Pandemic on HbA1c Testing: Prioritization of High-Risk Cases and Impact of Social Deprivation
Introduction Studies show that the COVID-19 pandemic disproportionately affected people with diabetes and those from disadvantaged backgrounds. During the first 6 months of the UK lockdown, > 6.6 M glycated haemoglobin (HbA1c) tests were missed. We now report variability in the recovery of HbA1c testing, and its association with diabetes control and demographic characteristics. Methods In a service evaluation, we examined HbA1c testing across ten UK sites (representing 9.9% of England’s population) from January 2019 to December 2021. We compared monthly requests from April 2020 to those in the equivalent 2019 months. We examined effects of (i) HbA1c level, (ii) between-practice variability, and (iii) practice demographics. Results In April 2020, monthly requests dropped to 7.9–18.1% of 2019 volumes. By July 2020, testing had recovered to 61.7–86.9% of 2019 levels. During April–June 2020, we observed a 5.1-fold variation in the reduction of HbA1c testing between general practices (12.4–63.8% of 2019 levels). There was evidence of limited prioritization of testing for patients with HbA1c > 86 mmol/mol during April–June 2020 (4.6% of total tests vs. 2.6% during 2019). Testing in areas with the highest social disadvantage was lower during the first lockdown (April–June 2020; trend test p < 0.001) and two subsequent periods (July–September and October–December 2020; both p < 0.001). By February 2021, testing in the highest deprivation group had a cumulative fall in testing of 34.9% of 2019 levels versus 24.6% in those in the lowest group. Conclusion Our findings highlight that the pandemic response had a major impact on diabetes monitoring and screening. Despite limited test prioritization in the > 86 mmol/mol group, this failed to acknowledge that those in the 59–86 mmol/mol group require consistent monitoring to achieve the best outcomes. Our findings provide additional evidence that those from poorer backgrounds were disproportionately disadvantaged. Healthcare services should redress this health inequality.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Health Inequality and its link to HbA1c Test Recovery in a Developed Health Economy: In a 'Nearly Post COVID-19' World
Background: We previously showed that in first 6 months of the UK Covid-19(C19) pandemic >6.6million HbA1c tests were missed, including 1.4million in people with diabetes(DM). Furthermore, C19 more significantly impacts people with DM / socioeconomically disadvantaged individuals. Aim: To examine variability in recovery rate of HbA1c testing, and links to demographics, including deprivation status. Methods: We examined HbA1c tests across 7 UK sites (570 general practices; 4.57m population) between Oct-2017 and Dec-2021. We compared monthly tests during 4 periods: Apr-Jun2020 (C19 Impact Period; CIP1), Jul-Dec2020 (Inter-Lockdown Recovery; ILR), Jan-Feb2021 (CIP2) and Mar-Dec2021 (Post-Lockdown Recovery; PLR), with the equivalent period in 2019. We then examined effect of practice size/diabetes prevalence/proportion aged>65 years and deprivation score. Results: For all 7 centres, monthly requests dropped by 85.2-89.4% of the mean monthly 2019 request numbers in Apr-2020. During the following 3 periods, degree of recovery showed greater variability between centres (ILR: 74.0-93.2%, CIP2: 78.6-94.2%, PLR: 89.0-105.7%). No link between age/practice size/diabetes prevalence and post-pandemic recovery was seen. Return to pre-pandemic levels during the two recovery periods was associated with deprivation status. Compared with equivalent pre-pandemic periods, HbA1c testing during the PLR period was lower in higher deprivation areas (deciles 6-10: 91.3-93.5% of 2019 levels) than those with lower deprivation (deciles 1-5:96.2-99.7% of 2019 levels; PP<0.001). This trend was not evident during CIP1/CIP2. UK-wide, these account for ~582,000 and ~358,000 additional missed tests during the ILR and PLR periods in areas at greatest social disadvantage. Conclusions: C19 continues to have a major impact on diabetes management/HbA1c testing with some centres yet to return to pre-pandemic testing levels. This appears most significant in areas of greatest socio-economic deprivation.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Health Inequality and its link to HbA1c Test Recovery in a Developed Health Economy: In a 'Nearly Post COVID-19' World
Background: We previously showed that in first 6 months of the UK Covid-19(C19) pandemic >6.6million HbA1c tests were missed, including 1.4million in people with diabetes(DM). Furthermore, C19 more significantly impacts people with DM / socioeconomically disadvantaged individuals. Aim: To examine variability in recovery rate of HbA1c testing, and links to demographics, including deprivation status. Methods: We examined HbA1c tests across 7 UK sites (570 general practices; 4.57m population) between Oct-2017 and Dec-2021. We compared monthly tests during 4 periods: Apr-Jun2020 (C19 Impact Period; CIP1), Jul-Dec2020 (Inter-Lockdown Recovery; ILR), Jan-Feb2021 (CIP2) and Mar-Dec2021 (Post-Lockdown Recovery; PLR), with the equivalent period in 2019. We then examined effect of practice size/diabetes prevalence/proportion aged>65 years and deprivation score. Results: For all 7 centres, monthly requests dropped by 85.2-89.4% of the mean monthly 2019 request numbers in Apr-2020. During the following 3 periods, degree of recovery showed greater variability between centres (ILR: 74.0-93.2%, CIP2: 78.6-94.2%, PLR: 89.0-105.7%). No link between age/practice size/diabetes prevalence and post-pandemic recovery was seen. Return to pre-pandemic levels during the two recovery periods was associated with deprivation status. Compared with equivalent pre-pandemic periods, HbA1c testing during the PLR period was lower in higher deprivation areas (deciles 6-10: 91.3-93.5% of 2019 levels) than those with lower deprivation (deciles 1-5:96.2-99.7% of 2019 levels; PP<0.001). This trend was not evident during CIP1/CIP2. UK-wide, these account for ~582,000 and ~358,000 additional missed tests during the ILR and PLR periods in areas at greatest social disadvantage. Conclusions: C19 continues to have a major impact on diabetes management/HbA1c testing with some centres yet to return to pre-pandemic testing levels. This appears most significant in areas of greatest socio-economic deprivation.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Thyroid function testing in people treated with Lithium: We are doing more thyroid tests than is necessary
Introduction: Lithium is a common pharmacological intervention for the treatment of bipolar affective disorder and is advocated by clinical practice guidelines (NICE 2021). Blood test monitoring is essential for management of lithium treatment and UK NICE guidance recommends 6-monthly serum testing of thyroid function. We here examine conformity to guidance and the consequences of monitoring outside these intervals. Methods: We extracted serum lithium/thyroid hormone results at one centre Jan 2009-Dec 2020. We identified 266 patients who started lithium during this period with no history of thyroid abnormality within the previous 2 years and were at risk of developing thyroid abnormalities. We determined interval between tests, time between onset of lithium testing and first TSH outside laboratory reference range and assessed the impact of testing outside recommended 6-monthly intervals. Results: The most common testing frequency was 3-monthly (±1month), accounting for 37.3% of test intervals. Kaplan-Meier analysis showed that most thyroid dysfunction manifests within 3 years (proportion with abnormal TSH at 3 years=91.4%, 19.9% of total patients). In the first 3 months from commencing lithium therapy, 8 patients developed subclinical hypothyroidism and had clinical follow-up data available. Of these, half spontaneously normalised without clinical intervention. In the remaining patients, thyroxine replacement was only initiated after multiple episodes of subclinical hypothyroidism (median2 years after initiating lithium, range 6 months-3 years). Conclusions: Our data suggest that thyroid function tests are typically requested too frequently in patients on lithium, potentially resulting in over-diagnosis of thyroid abnormalities. 90.4% of TSH tests were outside the recommended 6-monthly (±1 month) interval. There was no evidence that early detection of abnormal thyroid results leads to earlier treatment. The initial thyroid dysfunction spontaneously resolved in half of cases without intervention. Importantly more than 90% of patients who developed thyroid dysfunction did so within three years of commencing lithium.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Thyroid function testing in people treated with Lithium: We are doing more thyroid tests than is necessary
Introduction: Lithium is a common pharmacological intervention for the treatment of bipolar affective disorder and is advocated by clinical practice guidelines (NICE 2021). Blood test monitoring is essential for management of lithium treatment and UK NICE guidance recommends 6-monthly serum testing of thyroid function. We here examine conformity to guidance and the consequences of monitoring outside these intervals. Methods: We extracted serum lithium/thyroid hormone results at one centre Jan 2009-Dec 2020. We identified 266 patients who started lithium during this period with no history of thyroid abnormality within the previous 2 years and were at risk of developing thyroid abnormalities. We determined interval between tests, time between onset of lithium testing and first TSH outside laboratory reference range and assessed the impact of testing outside recommended 6-monthly intervals. Results: The most common testing frequency was 3-monthly (±1month), accounting for 37.3% of test intervals. Kaplan-Meier analysis showed that most thyroid dysfunction manifests within 3 years (proportion with abnormal TSH at 3 years=91.4%, 19.9% of total patients). In the first 3 months from commencing lithium therapy, 8 patients developed subclinical hypothyroidism and had clinical follow-up data available. Of these, half spontaneously normalised without clinical intervention. In the remaining patients, thyroxine replacement was only initiated after multiple episodes of subclinical hypothyroidism (median2 years after initiating lithium, range 6 months-3 years). Conclusions: Our data suggest that thyroid function tests are typically requested too frequently in patients on lithium, potentially resulting in over-diagnosis of thyroid abnormalities. 90.4% of TSH tests were outside the recommended 6-monthly (±1 month) interval. There was no evidence that early detection of abnormal thyroid results leads to earlier treatment. The initial thyroid dysfunction spontaneously resolved in half of cases without intervention. Importantly more than 90% of patients who developed thyroid dysfunction did so within three years of commencing lithium.
- Open Access
- 16 May 2022
- Published by Wiley in Journal of Diabetes Research
- Vol. 2022, 1-11
Variability in Test Interval Is Linked to Glycated Haemoglobin (HbA1c) Trajectory over Time
Aims. We previously showed that the glycated haemoglobin (HbA1c) testing frequency links to diabetes control. Here, we examine the effect of variability in test interval, adjusted for the frequency, on change in HbA1c (ΔHbA1c). Materials & Methods. HbA1c results were collected on 83,872 people with HbA1c results at baseline and 5 years (±3 months) later and ≥6 tests during this period. We calculated the standard deviation (SD) of test interval for each individual and examined the link between deciles of SD of the test interval and ΔHbA1c level, stratified by baseline HbA1c. Results. In general, less variability in testing frequency (more consistent monitoring) was associated with better diabetes control. This was most evident with moderately raised baseline HbA1c levels (7.0–9.0% (54–75 mmol/mol)). For example, in those with a starting HbA1c of 7.0–7.5% (54–58 mmol/mol), the lowest SD decile was associated with little change in HbA1c over 5 years, while for those with the highest decile, HbA1c rose by 0.4–0.6% (4–6 mmol/mol; ). Multivariate analysis showed that the association was independent of the age/sex/hospital site. Subanalysis suggested that the effect was most pronounced in those aged Conclusions. These findings indicate that the consistency of testing interval, not the just number of tests/year, is important in maintaining diabetes control, especially in those with moderately raised HbA1c levels. Systems to improve regularity of HbA1c testing are therefore needed, especially given the impact of COVID-19 on diabetes monitoring.
- 16 May 2022
- Published by Wiley in Journal of Diabetes Research
- Vol. 2022, 1-11
Open AccessVariability in Test Interval Is Linked to Glycated Haemoglobin (HbA1c) Trajectory over Time
Aims. We previously showed that the glycated haemoglobin (HbA1c) testing frequency links to diabetes control. Here, we examine the effect of variability in test interval, adjusted for the frequency, on change in HbA1c (ΔHbA1c). Materials & Methods. HbA1c results were collected on 83,872 people with HbA1c results at baseline and 5 years (±3 months) later and ≥6 tests during this period. We calculated the standard deviation (SD) of test interval for each individual and examined the link between deciles of SD of the test interval and ΔHbA1c level, stratified by baseline HbA1c. Results. In general, less variability in testing frequency (more consistent monitoring) was associated with better diabetes control. This was most evident with moderately raised baseline HbA1c levels (7.0–9.0% (54–75 mmol/mol)). For example, in those with a starting HbA1c of 7.0–7.5% (54–58 mmol/mol), the lowest SD decile was associated with little change in HbA1c over 5 years, while for those with the highest decile, HbA1c rose by 0.4–0.6% (4–6 mmol/mol; ). Multivariate analysis showed that the association was independent of the age/sex/hospital site. Subanalysis suggested that the effect was most pronounced in those aged Conclusions. These findings indicate that the consistency of testing interval, not the just number of tests/year, is important in maintaining diabetes control, especially in those with moderately raised HbA1c levels. Systems to improve regularity of HbA1c testing are therefore needed, especially given the impact of COVID-19 on diabetes monitoring.
- Open Access
- 17 December 2021
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 5 (2) , e00302
The experience of blood glucose monitoring in people with type 2 diabetes mellitus (T2DM)
Background: Finger prick blood glucose (BG) monitoring remains a mainstay of management in people with type 2 diabetes (T2DM) who take sulphonylurea (SU) drugs or insulin.We recently examined patient experience of BG monitoring in people with type 1 diabetes (T1DM). There has not been any recent comprehensive assessment of the performance of BG monitoring strips or the patient experience of BG strips in people with T2DM in the UK.Methods: An online self‐reported questionnaire containing 44 questions, prepared following consultation with clinicians and patients, was circulated to people with T2DM. 186 responders provided completed responses (25.5% return rate). Fixed responses were coded numerically (eg not confident = 0 fairly confident = 1).Results: Of responders, 84% were treated with insulin in addition to other agents. 75% reported having had an HbA1c check in the previous 6 months.For those with reported HbA1c ≥ 65 mmol/mol, a majority of people (70%) were concerned or really concerned about the shorter term consequences of running a high HbA1c This contrasted with those who did not know their recent HbA1c, of whom only 33% were concerned/really concerned and those with HbA1c <65 mmol/mol of whom 35% were concerned.Regarding BG monitoring/insulin adjustment, only 25% of responders reported having sufficient information with 13% believing that the accuracy and precision of their BG metre was being independently checked. Only 9% recalled discussing BG metre accuracy when their latest metre was provided and only 7% were aware of the International Standardisation Organisation (ISO) standards for BG metres. 77% did not recall discussing BG metre performance with a healthcare professional.Conclusion: The group surveyed comprised engaged people with T2DM but even within this group there was significant variation in (a) awareness of shorter term risks, (b) confidence in their ability to implement appropriate insulin dosage (c) awareness of the limitations of BG monitoring technology. There is clearly an area where changes in education/support would benefit many.
- 17 December 2021
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 5 (2) , e00302
Open AccessThe experience of blood glucose monitoring in people with type 2 diabetes mellitus (T2DM)
Background: Finger prick blood glucose (BG) monitoring remains a mainstay of management in people with type 2 diabetes (T2DM) who take sulphonylurea (SU) drugs or insulin.We recently examined patient experience of BG monitoring in people with type 1 diabetes (T1DM). There has not been any recent comprehensive assessment of the performance of BG monitoring strips or the patient experience of BG strips in people with T2DM in the UK.Methods: An online self‐reported questionnaire containing 44 questions, prepared following consultation with clinicians and patients, was circulated to people with T2DM. 186 responders provided completed responses (25.5% return rate). Fixed responses were coded numerically (eg not confident = 0 fairly confident = 1).Results: Of responders, 84% were treated with insulin in addition to other agents. 75% reported having had an HbA1c check in the previous 6 months.For those with reported HbA1c ≥ 65 mmol/mol, a majority of people (70%) were concerned or really concerned about the shorter term consequences of running a high HbA1c This contrasted with those who did not know their recent HbA1c, of whom only 33% were concerned/really concerned and those with HbA1c <65 mmol/mol of whom 35% were concerned.Regarding BG monitoring/insulin adjustment, only 25% of responders reported having sufficient information with 13% believing that the accuracy and precision of their BG metre was being independently checked. Only 9% recalled discussing BG metre accuracy when their latest metre was provided and only 7% were aware of the International Standardisation Organisation (ISO) standards for BG metres. 77% did not recall discussing BG metre performance with a healthcare professional.Conclusion: The group surveyed comprised engaged people with T2DM but even within this group there was significant variation in (a) awareness of shorter term risks, (b) confidence in their ability to implement appropriate insulin dosage (c) awareness of the limitations of BG monitoring technology. There is clearly an area where changes in education/support would benefit many.
- 13 October 2021
- Published by BMJ in Journal of Clinical Pathology
- Vol. 76 (3) , 177-184
Assessment of the effect of the COVID-19 pandemic on UK HbA1c testing: implications for diabetes management and diagnosis
Aims The COVID-19 pandemic, and the focus on mitigating its effects, has disrupted diabetes healthcare services worldwide. We aimed to quantify the effect of the pandemic on diabetes diagnosis/management, using glycated haemoglobin (HbA1c) as surrogate, across six UK centres. Methods Using routinely collected laboratory data, we estimated the number of missed HbA1c tests for ‘diagnostic’/‘screening’/‘management’ purposes during the COVID-19 impact period (CIP; 23 March 2020 to 30 September 2020). We examined potential impact in terms of: (1) diabetes control in people with diabetes and (2) detection of new diabetes and prediabetes cases. Results In April 2020, HbA1c test numbers fell by ~80%. Overall, across six centres, 369 871 tests were missed during the 6.28 months of the CIP, equivalent to >6.6 million tests nationwide. We identified 79 131 missed ‘monitoring’ tests in people with diabetes. In those 28 564 people with suboptimal control, this delayed monitoring was associated with a 2–3 mmol/mol HbA1c increase. Overall, 149 455 ‘screening’ and 141 285 ‘diagnostic’ tests were also missed. Across the UK, our findings equate to 1.41 million missed/delayed diabetes monitoring tests (including 0.51 million in people with suboptimal control), 2.67 million screening tests in high-risk groups (0.48 million within the prediabetes range) and 2.52 million tests for diagnosis (0.21 million in the pre-diabetes range; ~70 000 in the diabetes range). Conclusions Our findings illustrate the widespread collateral impact of implementing measures to mitigate the impact of COVID-19 in people with, or being investigated for, diabetes. For people with diabetes, missed tests will result in further deterioration in diabetes control, especially in those whose HbA1c levels are already high.
- 13 October 2021
- Published by BMJ in Journal of Clinical Pathology
- Vol. 76 (3) , 177-184
Assessment of the effect of the COVID-19 pandemic on UK HbA1c testing: implications for diabetes management and diagnosis
Aims The COVID-19 pandemic, and the focus on mitigating its effects, has disrupted diabetes healthcare services worldwide. We aimed to quantify the effect of the pandemic on diabetes diagnosis/management, using glycated haemoglobin (HbA1c) as surrogate, across six UK centres. Methods Using routinely collected laboratory data, we estimated the number of missed HbA1c tests for ‘diagnostic’/‘screening’/‘management’ purposes during the COVID-19 impact period (CIP; 23 March 2020 to 30 September 2020). We examined potential impact in terms of: (1) diabetes control in people with diabetes and (2) detection of new diabetes and prediabetes cases. Results In April 2020, HbA1c test numbers fell by ~80%. Overall, across six centres, 369 871 tests were missed during the 6.28 months of the CIP, equivalent to >6.6 million tests nationwide. We identified 79 131 missed ‘monitoring’ tests in people with diabetes. In those 28 564 people with suboptimal control, this delayed monitoring was associated with a 2–3 mmol/mol HbA1c increase. Overall, 149 455 ‘screening’ and 141 285 ‘diagnostic’ tests were also missed. Across the UK, our findings equate to 1.41 million missed/delayed diabetes monitoring tests (including 0.51 million in people with suboptimal control), 2.67 million screening tests in high-risk groups (0.48 million within the prediabetes range) and 2.52 million tests for diagnosis (0.21 million in the pre-diabetes range; ~70 000 in the diabetes range). Conclusions Our findings illustrate the widespread collateral impact of implementing measures to mitigate the impact of COVID-19 in people with, or being investigated for, diabetes. For people with diabetes, missed tests will result in further deterioration in diabetes control, especially in those whose HbA1c levels are already high.
- 9 June 2021
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (9) , e14447
Inadequate postpartum screening for type 2 diabetes in women with previous gestation diabetes mellitus: A retrospective audit of practice over 17 years
Introduction Women with gestational diabetes (GDM) are at greatly increased risk of type 2 diabetes (T2DM). The UK guidance recommends screening for T2DM at around 6 weeks post-partum and annually thereafter. We evaluated conformity to this guidance in two separate time periods. Methods The proportion of tests performed within guidance was assessed using longitudinal plasma glucose and glycated haemoglobin data in two cohorts (1999-2007, n=251; 2015-2016, n=260) from hospital records on women previously diagnosed with GDM. Results In the 1999-2007 and 2015-2016 cohorts, 59.8% and 35.0% of women had the recommended post-partum testing, respectively (p<0.001); just 13.5% and 14.2%, respectively, underwent the first annual test on time. During long-term follow-up of the 1999-2007 cohort (median follow-up: 12.3 years), the proportion of women tested in any given year averaged 34.2% over a 17-year period; there was a progressive decline in the proportion of women receiving a yearly test with time since delivery (p=0.002). Over the follow-up period, 85 women from the 1999-2007 cohort developed blood test results in the diabetic range with a median time to presumed DM diagnosis of 5.2 years (range 0.11-15.95 years). Kaplan-Meier analysis showed that 18.8% of women had blood test results in the diabetes range by 5 years and 37.8% by 10 years post-partum. Conclusions Despite high profile guidelines and a clear clinical rationale to screen women with a past diagnosis of GDM, many women did not receive adequate screening for T2DM, both in the short- and long-term. This suggests alternative approaches are needed to ensure effective follow-up of this high-risk group. To have an impact, interventions need to be tailored to a young, generally healthy group in which traditional approaches to follow-up may not be best suited.
- 9 June 2021
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (9) , e14447
Inadequate postpartum screening for type 2 diabetes in women with previous gestation diabetes mellitus: A retrospective audit of practice over 17 years
Introduction Women with gestational diabetes (GDM) are at greatly increased risk of type 2 diabetes (T2DM). The UK guidance recommends screening for T2DM at around 6 weeks post-partum and annually thereafter. We evaluated conformity to this guidance in two separate time periods. Methods The proportion of tests performed within guidance was assessed using longitudinal plasma glucose and glycated haemoglobin data in two cohorts (1999-2007, n=251; 2015-2016, n=260) from hospital records on women previously diagnosed with GDM. Results In the 1999-2007 and 2015-2016 cohorts, 59.8% and 35.0% of women had the recommended post-partum testing, respectively (p<0.001); just 13.5% and 14.2%, respectively, underwent the first annual test on time. During long-term follow-up of the 1999-2007 cohort (median follow-up: 12.3 years), the proportion of women tested in any given year averaged 34.2% over a 17-year period; there was a progressive decline in the proportion of women receiving a yearly test with time since delivery (p=0.002). Over the follow-up period, 85 women from the 1999-2007 cohort developed blood test results in the diabetic range with a median time to presumed DM diagnosis of 5.2 years (range 0.11-15.95 years). Kaplan-Meier analysis showed that 18.8% of women had blood test results in the diabetes range by 5 years and 37.8% by 10 years post-partum. Conclusions Despite high profile guidelines and a clear clinical rationale to screen women with a past diagnosis of GDM, many women did not receive adequate screening for T2DM, both in the short- and long-term. This suggests alternative approaches are needed to ensure effective follow-up of this high-risk group. To have an impact, interventions need to be tailored to a young, generally healthy group in which traditional approaches to follow-up may not be best suited.